Summary
24.88 -0.23(-0.90%)11/20/2024
Pfizer Inc. (PFE)
PFE reported last earnings on 2024-10-29 after the market. An EPS of $1.06 was observed compared to an estimated EPS of $0.614, resulting in a surprise value of $0.45. A revenue of $17,702 million was observed compared to an estimated revenue of $14,921 million, resulting in a surprise value of $2,781 Million.
Pfizer Inc. (PFE)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| -0.16 | -6.90 | -14.02 | -13.96 | -12.73 | -17.03 | -20.98 | 13,987.74 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
Earnings
Fundamental Ratings
| Category | Rating |
| Main Rating | A- |
| Recommended Rating | Buy |
| DCF | Strong Buy |
| ROE | Strong Buy |
| ROA | Strong Buy |
| Debt/Equity | Strong Sell |
| P/E | Sell |
| P/B | Neutral |
| Trading Data | ||
| Close | 24.88 | |
| Open | 25.07 | |
| High | 25.10 | |
| Low | 24.65 | |
| Volume | 36,209,796 | |
| Change | -0.04 | |
| Change % | -0.16 | |
| Avg Volume (20 Days) | 42,270,817 | |
| Volume/Avg Volume (20 Days) Ratio | 0.86 | |
| 52 Week Range | 24.48 - 31.54 | |
| Price vs 52 Week High | -21.13% | |
| Price vs 52 Week Low | 1.61% | |
| Range | -0.78 | |
| Gap Up/Down | -0.03 | |
Fundamentals | ||
| Market Capitalization (Mln) | 162,294 | |
| EBIDTA | 9,621,000,192 | |
| PE Ratio | 0.0000 | |
| PEG Ratio | 0.2560 | |
| WallStreet Target Price | 31.37 | |
| Book Value | 16.2840 | |
| Earnings Per Share | -0.0500 | |
| EPS Estimate Current Quarter | 0.5200 | |
| EPS Estimate Next Quarter | 0.4400 | |
| EPS Estimate Current Year | 2.3600 | |
| EPS Estimate Next Year | 2.7600 | |
| Diluted EPS (TTM) | -0.0500 | |
| Revenues | ||
| Profit Marging | -0.0056 | |
| Operating Marging (TTM) | 0.3163 | |
| Return on asset (TTM) | 0.0093 | |
| Return on equity (TTM) | -0.0026 | |
| Revenue TTM | 54,889,000,960 | |
| Revenue per share TTM | 9.7170 | |
| Quarterly Revenue Growth (YOY) | -0.1950 | |
| Quarterly Earnings Growth (YOY) | -0.4340 | |
| Gross Profit (TTM) | 66,233,000,000 | |
| Dividends | ||
| Dividend Share | 1.6500 | |
| Dividend Yield | 0.0600 | |
| Valuations | ||
| Trailing PE | 0.0000 | |
| Forward PE | 11.6686 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 1.6451 | |
| Revenue Enterprise Value | 3.4975 | |
| EBITDA Enterprise Value | 21.4072 | |
| Shares | ||
| Shares Outstanding | 5,666,590,208 | |
| Shares Float | 5,657,809,679 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.01 | |
| Insider (%) | 0.05 | |
| Institutions (%) | 70.15 | |
11/21 04:25 EST - fool.com
2 Dividend Stocks That Pay More Than 6% That Retirees Can Safely Buy and Hold for Years
2 Dividend Stocks That Pay More Than 6% That Retirees Can Safely Buy and Hold for Years
2 Dividend Stocks That Pay More Than 6% That Retirees Can Safely Buy and Hold for Years
2 Dividend Stocks That Pay More Than 6% That Retirees Can Safely Buy and Hold for Years
11/21 04:00 EST - businesswire.com
Zai Lab and Pfizer Announce Strategic Collaboration on the Novel Antibacterial Drug XACDURO® (Sulbactam-Durlobactam)
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab (“Zai Lab”, NASDAQ: ZLAB; HKEX: 9688) and Pfizer (“Pfizer”, NYSE: PFE) announced today a strategic collaboration for the novel antibacterial drug XACDURO® (sulbactam-durlobactam) in mainland China. Pfizer's affiliated companies will be...
Zai Lab and Pfizer Announce Strategic Collaboration on the Novel Antibacterial Drug XACDURO® (Sulbactam-Durlobactam)
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab (“Zai Lab”, NASDAQ: ZLAB; HKEX: 9688) and Pfizer (“Pfizer”, NYSE: PFE) announced today a strategic collaboration for the novel antibacterial drug XACDURO® (sulbactam-durlobactam) in mainland China. Pfizer's affiliated companies will be...
11/20 15:00 EST - zacks.com
5 Year-to-Date Laggards to Buy Amid Solid Near-Term Upside Potential
These five laggards of this year have double-digit upside left for the rest of 2024. These are: ADBE, PFE, DG, SNAP, RYAAY.
5 Year-to-Date Laggards to Buy Amid Solid Near-Term Upside Potential
These five laggards of this year have double-digit upside left for the rest of 2024. These are: ADBE, PFE, DG, SNAP, RYAAY.
11/20 10:34 EST - 247wallst.com
Over 60? These 2 Dividend Stocks are a Better Bet Than T-Bills
The appetite for high-risk investments really increased following Donald Trump's presidential victory.
Over 60? These 2 Dividend Stocks are a Better Bet Than T-Bills
The appetite for high-risk investments really increased following Donald Trump's presidential victory.
11/20 09:26 EST - 247wallst.com
Baby Boomers: 3 Top Defensive Stocks to Add in 2024 and Hold Through Retirement
Last year, the S&P 500 reached new highs despite geopolitical tensions and market pressures.
Baby Boomers: 3 Top Defensive Stocks to Add in 2024 and Hold Through Retirement
Last year, the S&P 500 reached new highs despite geopolitical tensions and market pressures.
11/20 07:34 EST - marketwatch.com
Pfizer names oncology chief and company veteran Boshoff as chief scientific officer
The drug company had been searching for a new chief scientific officer since July with Mikael Dolsten leaving after 15 years at the company.
Pfizer names oncology chief and company veteran Boshoff as chief scientific officer
The drug company had been searching for a new chief scientific officer since July with Mikael Dolsten leaving after 15 years at the company.
11/20 06:45 EST - businesswire.com
Pfizer Announces New Chief Scientific Officer and President, Research & Development
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that after a comprehensive internal and external selection process, the company is appointing Chris Boshoff, M.D., PhD, as Chief Scientific Officer and President, Research & Development effective January 1, 2025. Dr. Boshoff, who...
Pfizer Announces New Chief Scientific Officer and President, Research & Development
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that after a comprehensive internal and external selection process, the company is appointing Chris Boshoff, M.D., PhD, as Chief Scientific Officer and President, Research & Development effective January 1, 2025. Dr. Boshoff, who...
11/20 06:27 EST - reuters.com
Pfizer names Chris Boshoff as new R&D chief, WSJ reports
Pfizer has named company veteran Chris Boshoff, who led the drugmaker's cancer research and marketing for more than a year, as its R&D chief, WSJ reported on Wednesday.
Pfizer names Chris Boshoff as new R&D chief, WSJ reports
Pfizer has named company veteran Chris Boshoff, who led the drugmaker's cancer research and marketing for more than a year, as its R&D chief, WSJ reported on Wednesday.
11/20 06:15 EST - wsj.com
Pfizer Names New R&D Chief
Company veteran Chris Boshoff, who has led Pfizer's cancer research and marketing for more than a year, will become chief scientific officer starting Jan. 1.
Pfizer Names New R&D Chief
Company veteran Chris Boshoff, who has led Pfizer's cancer research and marketing for more than a year, will become chief scientific officer starting Jan. 1.
11/20 05:48 EST - fool.com
Is It Time to Sell Eli Lilly and Pfizer Stocks?
Is It Time to Sell Eli Lilly and Pfizer Stocks?
Is It Time to Sell Eli Lilly and Pfizer Stocks?
Is It Time to Sell Eli Lilly and Pfizer Stocks?
11/20 04:00 EST - businesswire.com
European Commission Approves Pfizer's HYMPAVZI™ (marstacimab) for the Treatment of Adults and Adolescents with Severe Hemophilia A or B Without Inhibitors
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today that the European Commission (EC) has granted marketing authorization for HYMPAVZI™ (marstacimab) for the routine prophylaxis of bleeding episodes in patients 12 years of age and older weighing at least 35 kg with severe...
European Commission Approves Pfizer's HYMPAVZI™ (marstacimab) for the Treatment of Adults and Adolescents with Severe Hemophilia A or B Without Inhibitors
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today that the European Commission (EC) has granted marketing authorization for HYMPAVZI™ (marstacimab) for the routine prophylaxis of bleeding episodes in patients 12 years of age and older weighing at least 35 kg with severe...
11/19 18:00 EST - seekingalpha.com
If I Could Only Buy 2 High Dividend Yield Companies In November 2024: Both Yield Above 6%
I have selected Pfizer and Verizon as my top two high dividend yield companies to invest in for November 2024. Both pay an attractive Dividend Yield [FWD] of 6.14% (Pfizer) and 6.58% (Verizon) and have a relatively low Valuation (P/E Non-GAAP [FWD] Ratio of 9.34 (Pfizer) and 8.80 (Verizon). To...
If I Could Only Buy 2 High Dividend Yield Companies In November 2024: Both Yield Above 6%
I have selected Pfizer and Verizon as my top two high dividend yield companies to invest in for November 2024. Both pay an attractive Dividend Yield [FWD] of 6.14% (Pfizer) and 6.58% (Verizon) and have a relatively low Valuation (P/E Non-GAAP [FWD] Ratio of 9.34 (Pfizer) and 8.80 (Verizon). To...
11/19 17:05 EST - reuters.com
Pfizer loses bid to recoup $75 million left over from SEC settlement
A federal judge on Tuesday rejected Pfizer's bid to recoup about $75.2 million left over from a U.S. Securities and Exchange Commission settlement with billionaire Steven A. Cohen's hedge fund SAC Capital in an insider trading case.
Pfizer loses bid to recoup $75 million left over from SEC settlement
A federal judge on Tuesday rejected Pfizer's bid to recoup about $75.2 million left over from a U.S. Securities and Exchange Commission settlement with billionaire Steven A. Cohen's hedge fund SAC Capital in an insider trading case.
11/19 14:44 EST - benzinga.com
BridgeBio Pharma's Acoramidis Shows Competitive Edge Against Pfizer's Tafamidisa In Lucrative But Competitive ATTR-CM Market
On Monday, BridgeBio Pharma, Inc. BBIO presented initial outcomes from the ATTRibute-CM open-label extension (OLE) study of acoramidis in ATTR-CM at the American Heart Association Scientific Sessions.
BridgeBio Pharma's Acoramidis Shows Competitive Edge Against Pfizer's Tafamidisa In Lucrative But Competitive ATTR-CM Market
On Monday, BridgeBio Pharma, Inc. BBIO presented initial outcomes from the ATTRibute-CM open-label extension (OLE) study of acoramidis in ATTR-CM at the American Heart Association Scientific Sessions.
11/19 08:45 EST - zacks.com
These 4 Price-to-Sales Stocks Can Supercharge Your Portfolio Growth
The price-to-sales ratio is a convenient tool to gauge the value of stocks incurring losses or in an early development cycle. Stocks like AGR, SMP, GBX and PFE hold promise.
These 4 Price-to-Sales Stocks Can Supercharge Your Portfolio Growth
The price-to-sales ratio is a convenient tool to gauge the value of stocks incurring losses or in an early development cycle. Stocks like AGR, SMP, GBX and PFE hold promise.
11/18 15:00 EST - zacks.com
Buy 5 U.S. Bigwigs on the Dip for Sparkling Returns in the Short Term
Five stocks currently available at attractive valuations after sizeable corrections in prices are: PFE, NEM, UBER, ADBE, QCOM.
Buy 5 U.S. Bigwigs on the Dip for Sparkling Returns in the Short Term
Five stocks currently available at attractive valuations after sizeable corrections in prices are: PFE, NEM, UBER, ADBE, QCOM.
11/18 12:03 EST - proactiveinvestors.com
Medicus Pharma unveils ex-GSK and Pfizer senior as chief medical officer
Medicus Pharma (TSX-V:MDCX, NASDAQ:MDCX) Ltd has announced the appointment of Faisal Mehmud, formerly of GSK PLC (LSE:GSK, NYSE:GSK) and Pfizer Inc (NYSE:PFE, ETR:PFE), as chief medical officer. Mehmud has over 20 years of experience as a senior medical executive in clinical development, medical...
Medicus Pharma unveils ex-GSK and Pfizer senior as chief medical officer
Medicus Pharma (TSX-V:MDCX, NASDAQ:MDCX) Ltd has announced the appointment of Faisal Mehmud, formerly of GSK PLC (LSE:GSK, NYSE:GSK) and Pfizer Inc (NYSE:PFE, ETR:PFE), as chief medical officer. Mehmud has over 20 years of experience as a senior medical executive in clinical development, medical...
11/18 06:45 EST - fool.com
2 High-Yield Dividend Stocks I Can't Stop Buying
2 High-Yield Dividend Stocks I Can't Stop Buying
2 High-Yield Dividend Stocks I Can't Stop Buying
2 High-Yield Dividend Stocks I Can't Stop Buying
11/15 22:03 EST - forbes.com
As Drug Maker Stocks Fall, Pressure Builds On PhRMA To Derail RFK, Jr.
Stocks of major drug makers and biotech companies tumbled in trading late this week after President-elect Donald Trump announced that he wants vaccine skeptic Robert F. Kennedy Jr. to lead the U.S. Department of Health and Human Services.
As Drug Maker Stocks Fall, Pressure Builds On PhRMA To Derail RFK, Jr.
Stocks of major drug makers and biotech companies tumbled in trading late this week after President-elect Donald Trump announced that he wants vaccine skeptic Robert F. Kennedy Jr. to lead the U.S. Department of Health and Human Services.
11/15 14:31 EST - fastcompany.com
Moderna, Lily, Novavax, and Pfizer stocks fall after Trump nominates RFK Jr. as health secretary
Shares in some of America's largest drug manufacturers tumbled yesterday after President-elect Donald Trump announced Robert F. Kennedy Jr. as his pick for secretary of the Department of Health and Human Services (HHS).
Moderna, Lily, Novavax, and Pfizer stocks fall after Trump nominates RFK Jr. as health secretary
Shares in some of America's largest drug manufacturers tumbled yesterday after President-elect Donald Trump announced Robert F. Kennedy Jr. as his pick for secretary of the Department of Health and Human Services (HHS).